Enzyme Replacement Therapy Market Regional Analysis:
Asia Pacific Market Insights
The Asia Pacific enzyme replacement therapy market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035, owing to the growing number of patient population suffering from rare disorders, rising disposable income, growth in the healthcare sector, and an increase in government support. According to the Economist Intelligence Unit, 258 million individuals in Asia and the Pacific region suffer from rare diseases.
Europe Market Insights
Europe will hold second-largest share of the worldwide market. The increase can be credited primarily to supportive regulatory policies in a few European nations for different infrequent lysosomal ailments, including Gaucher disease, MPS, and others. As per F1000 Research Ltd., the Polish National Health Fund, for instance, implemented a national drug program in 2019, with the first remuneration in ERT for Fabry disease. Furthermore, rapid advancements in medical infrastructure and a growing preference for therapeutic approaches for rare diseases drive market expansion in this region.
